Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations

Patients with acquired resistance to first-generation EGFR TKIs, including those with the T790M mutation, may still respond to EGFR-targeted therapy. Combination afatinib and panitumumab may represent a viable therapeutic option for patients with acquired resistance to first-generation EGFR TKIs. Optimal management of LMC is an ongoing challenge, and the efficacy of targeted therapies remains undefined. (C) 2015 Elsevier Inc. All rights reserved.